share_log

Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE

Benzinga ·  2021/06/17 10:59
Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-1002 at PPMD 2021.
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする